151 related articles for article (PubMed ID: 36508173)
1. Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer.
Mortensen C; Steffensen KD; Simonsen E; Herskind K; Madsen JS; Olsen DA; Iversen DB; Bergmann TK; Pottegård A; Stage TB
Pain; 2023 Jul; 164(7):1502-1511. PubMed ID: 36508173
[TBL] [Abstract][Full Text] [Related]
2. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients.
Karteri S; Bruna J; Argyriou AA; Mariotto S; Velasco R; Alemany M; Kalofonou F; Alberti P; Dinoto A; Velissaris D; Stradella A; Cavaletti G; Ferrari S; Kalofonos HP
J Peripher Nerv Syst; 2022 Jun; 27(2):166-174. PubMed ID: 35384143
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity.
Velasco R; Argyriou AA; Marco C; Mariotto S; Stradella A; Hernández J; Pernas S; Ferrari S; Bruna J
J Neurol; 2023 Jan; 270(1):531-537. PubMed ID: 36094631
[TBL] [Abstract][Full Text] [Related]
4. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers.
Kim SH; Kim KH; Hyun JW; Kim JH; Seo SS; Kim HJ; Park SY; Lim MC
Front Oncol; 2022; 12():942960. PubMed ID: 36059704
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy.
Huehnchen P; Schinke C; Bangemann N; Dordevic AD; Kern J; Maierhof SK; Hew L; Nolte L; Körtvelyessy P; Göpfert JC; Ruprecht K; Somps CJ; Blohmer JU; Sehouli J; Endres M; Boehmerle W
JCI Insight; 2022 Mar; 7(6):. PubMed ID: 35133982
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity.
Meregalli C; Fumagalli G; Alberti P; Canta A; Chiorazzi A; Monza L; Pozzi E; Carozzi VA; Blennow K; Zetterberg H; Cavaletti G; Marmiroli P
Arch Toxicol; 2020 Jul; 94(7):2517-2522. PubMed ID: 32333051
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin.
Burgess BL; Cho E; Honigberg L
Sci Rep; 2022 Sep; 12(1):15593. PubMed ID: 36114333
[TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study.
Argyriou AA; Karteri S; Bruna J; Mariotto S; Simo M; Velissaris D; Kalofonou F; Cavaletti G; Ferrari S; Kalofonos HP
Support Care Cancer; 2022 Feb; 30(2):1807-1814. PubMed ID: 34599664
[TBL] [Abstract][Full Text] [Related]
9. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
Pignata S; De Placido S; Biamonte R; Scambia G; Di Vagno G; Colucci G; Febbraro A; Marinaccio M; Lombardi AV; Manzione L; Cartenì G; Nardi M; Danese S; Valerio MR; de Matteis A; Massidda B; Gasparini G; Di Maio M; Pisano C; Perrone F
BMC Cancer; 2006 Jan; 6():5. PubMed ID: 16398939
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
Tanabe Y; Hashimoto K; Shimizu C; Hirakawa A; Harano K; Yunokawa M; Yonemori K; Katsumata N; Tamura K; Ando M; Kinoshita T; Fujiwara Y
Int J Clin Oncol; 2013 Feb; 18(1):132-8. PubMed ID: 22105895
[TBL] [Abstract][Full Text] [Related]
11. Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors.
Kober KM; Olshen A; Conley YP; Schumacher M; Topp K; Smoot B; Mazor M; Chesney M; Hammer M; Paul SM; Levine JD; Miaskowski C
Mol Pain; 2018; 14():1744806918816462. PubMed ID: 30426838
[TBL] [Abstract][Full Text] [Related]
12. Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel.
Xiong C; Chua KC; Stage TB; Priotti J; Kim J; Altman-Merino A; Chan D; Saraf K; Canato Ferracini A; Fattahi F; Kroetz DL
Clin Transl Sci; 2021 Mar; 14(2):568-581. PubMed ID: 33340242
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors.
Kober KM; Mazor M; Abrams G; Olshen A; Conley YP; Hammer M; Schumacher M; Chesney M; Smoot B; Mastick J; Paul SM; Levine JD; Miaskowski C
J Pain Symptom Manage; 2018 Dec; 56(6):908-919.e3. PubMed ID: 30172061
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
15. Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study.
Miyamoto T; Hiramoto S; Kanto A; Tsubota M; Fujitani M; Fukuyama H; Hatanaka S; Sekiguchi F; Koizumi Y; Kawabata A
J Pharmacol Sci; 2021 May; 146(1):49-57. PubMed ID: 33858655
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
[TBL] [Abstract][Full Text] [Related]
17. Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.
Li L; Li J; Zuo Y; Dang D; Frost JA; Yang Q
J Pain; 2019 May; 20(5):528-539. PubMed ID: 30471428
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Ghoreishi Z; Keshavarz S; Asghari Jafarabadi M; Fathifar Z; Goodman KA; Esfahani A
BMC Cancer; 2018 Oct; 18(1):958. PubMed ID: 30290775
[TBL] [Abstract][Full Text] [Related]
20. Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1.
Wilke C; Mengel D; Schöls L; Hengel H; Rakowicz M; Klockgether T; Durr A; Filla A; Melegh B; Schüle R; Reetz K; Jacobi H; Synofzik M
Neurology; 2022 May; 98(20):e1985-e1996. PubMed ID: 35264424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
